Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

Blood

Volumn 112, Issue 4, 2008, Pages 1424-1433

  Buglio, Daniela ^a   Georgakis, Georgios V ^a   Hanabuchi, Shino ^a   Arima, Kazuhiko ^a   Khaskhely, Noor M ^a   Liu, Yong Jun ^a   Younes, Anas ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DOXORUBICIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; INTERLEUKIN 5; MESSENGER RNA; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; STAT6 PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VORINOSTAT; ANTINEOPLASTIC AGENT; CCL17 PROTEIN, HUMAN; CYTOKINE; HISTONE DEACETYLASE; HYDROXAMIC ACID; STAT6 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; ENZYME ACTIVATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REED STERNBERG CELL; TH2 CELL; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; SECRETION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL17; CYTOKINES; DENDRITIC CELLS; HISTONE DEACETYLASES; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; STAT6 TRANSCRIPTION FACTOR; TH2 CELLS;

EID: 51649092609     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-133769     Document Type: Article

References (33)

1. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99: 4283-4297.
2. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. 2005; 105:4553-4560.
3. Baus D, Pfitzner E. Specific function of STAT3. SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer. 2006;118:1404-1413.
4. Cochet O, Frelin C, Peyron JF Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006;18:449- 455.
5. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-626.
6. Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, DusGhl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev. 2006;17:173-188.
7. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999:189:1939-1946.
8. Wirnsberger G, Hebenstreit D, Posselt G, Horejs- HoeckJ, Duschl A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006;36:1882-1891.
9. Liddiard K, Welch JS, Lozach J, Heinz S, Glass CK, Greaves DR. lnterleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol Biol. 2006;7:45.
10. van den Berg A. Visser L, Poppema S. High expression of the CC chemokine TARC in Reed- Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol. 1999;154:1685-1691.
11. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307:269-273.
12. UshmorovA, Leithauser F, Sakk O, et al. Epige- netic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107:2493-2500.
13. UshmorovA, RitzO, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood. 2004;104:3326-3334.
14. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma. 1993;9:1-25.
15. Georgakis GV, Li Y, Rassidakis GZ, Martinez- Valdez H, Medeiros LJ. Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17- demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephos-phorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res. 2006:12:584-590.
16. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673-680.
17. Zheng B, Fiumara P Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003:102:1019-1027.
18. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000; 97:10014-10019.
19. Shao Y. Gao Z. Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2004;101:18030-18035.
20. Amin HM, Saeed S,Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and down regulation of daxx in acute promyelo-cytic leukaemia with t(15;17). Br J Haematol. 2001;115:287-297.
21. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemo- therapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA. 2001 ;98:10833-10838.
22. Carew JS, Nawrocki ST Kahue GN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007;110:313-322.
23. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidyl- inositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006;132:503-511.
24. Garcia JF, Camacho Fl, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003; 101:681-689.
25. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential tor Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 2005;19: 936-944.
26. Fiumara P. Cabanillas F, Younes A. lnterleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood. 2001 ;98: 2877-2878.
27. Skinnider BF, Elia AJ, Gascoyne RD, et al. Inter- leukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250-255.
28. Wang JK, Xing FY. Human TSLP-Educated DCs. Cell Mol Immunol. 2008;5:99-106.
29. Liu YJ, Soumelis V, Watanabe N, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219.
30. Ziegler SR Liu YJ. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. Nat Immunol. 2006;7:709-714.
31. Wurster AL Rodgers VL White MF Rothstein TL Grusby MJ. lnterleukin-4-mediated protection of primary B cells from apoptosis through Stat6- dependent up-regulation of Bcl-xL. J Biol Chem. 2002;277:27169-27175.
32. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679-2684.
33. Younes A, Pro B, Fanale M, et al. Isotype- selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). ASH Annual Meeting Abstracts. Blood. 2007;110:2566.